Welcome to our dedicated page for Balance Labs SEC filings (Ticker: BLNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balance Labs, Inc. filings document the governance, officer-transition, and reporting records of a Delaware corporation pursuing a multi-line digital-asset operating business. Recent Form 8-K reports cover executive appointments, officer compensation arrangements, and board resignations, including statements on whether a departure involved a disagreement with company operations, policies, practices, controls, or financial matters.
The company’s Form 12b-25 filing records a delayed Annual Report on Form 10-K and describes the financial-information compilation, dissemination, and review process behind the late filing. Together, the filings address reporting status, management structure, board composition, and public-company controls for BLNC.
Balance Labs, Inc. reported a small net income of $177,803 for the quarter ended March 31, 2026, driven mainly by a non-cash gain of $706,056 from remeasuring a derivative tied to the CEO’s anti-dilution provision. Core operations remain weak, with revenue of $32,667 from a single advisory client and a loss from operations of $488,087, including $329,153 of stock-based compensation.
Cash used in operations was $142,609, leaving cash of $216,366 and a working capital deficit of $2,869,383 as of quarter-end. The company discloses substantial doubt about its ability to continue as a going concern without new financing and notes related-party debt of $500,000 that matured in May 2026 and remains outstanding, as well as a long‑defaulted $25,000 convertible note. Management also reports material weaknesses in internal controls, including limited formalized controls, no audit committee, and inadequate segregation of duties.
Balance Labs, Inc. reports full-year 2025 results showing an early-stage advisory business and a major balance sheet restructuring. The company generated just $6,000 in advisory revenue in 2025, then about $40,000 in the first quarter of 2026 as it began building its digital asset consulting practice.
Operating expenses surged to $13.1 million, driven largely by $12.7 million of non-cash stock-based compensation tied to share grants and CEO anti-dilution terms. A November 2025 debt-to-equity conversion turned $4.17 million of principal and interest into 16.7 million shares, creating a non-cash loss of $16.6 million but eliminating nearly all legacy debt.
As a result, Balance Labs posted a net loss of $31.8 million for 2025 and ended the year with cash of $358,975, total liabilities of $3.77 million, and a stockholders’ deficit of $(3.38) million. Auditors and management highlight substantial doubt about the company’s ability to continue as a going concern, noting that growth plans for a rules-based digital asset treasury depend on raising additional capital and expanding advisory revenues.
Balance Labs, Inc. notified the SEC that it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025 due to time constraints in compiling and reviewing required financial information. The company states it expects to file the Form 10-K no later than the fifteenth calendar day following the prescribed due date, pursuant to Rule 12b-25.
Balance Labs, Inc. has appointed Alexander Farkas as President and Chief Operating Officer, effective February 9, 2026. He brings experience from EV charging, military engineering, capital markets, digital assets, and solar-energy project financing, which the company notes aligns with its multi-line digital-asset operating focus.
The President Offer Letter provides an annual base salary of $120,000, with a target bonus of 65% of base salary and potential bonus of up to 125% of base salary, which he may elect to receive in common stock. The agreement has an initial two-year term with automatic two-year renewals and includes three months of base-salary continuation and COBRA benefits upon termination without cause or for good reason. Farkas is also subject to non-competition and other restrictive covenants and is the son of Board Chairman Michael Farkas.
Balance Labs, Inc. reported a change in its board of directors. On December 12, 2025, director Carmen Villegas resigned from the board effective immediately.
The company states that Ms. Villegas’s decision to step down was not due to any disagreement with Balance Labs regarding its operations, policies, practices, controls, or financial-related matters. The filing does not describe any replacement or additional board changes.
Balance Labs, Inc. reported a larger net loss as it restructured leadership and recognized a new derivative tied to its CEO agreement. Net loss was $3,594,664 for Q3 2025 (basic and diluted EPS $0.16 loss) and $3,747,212 for the nine months ended September 30, 2025. Operating cash outflow was $93,487 for the nine months.
Liquidity remains strained: cash was $4,512 as of September 30, 2025, with a working capital deficit of $8,675,685 and an accumulated deficit of $9,630,533. Management disclosed substantial doubt about continuing as a going concern. A derivative liability of $3,297,695 was recognized from an anti‑dilution feature in the CEO’s employment agreement, with a $3,425,796 loss recognized and a $128,101 remeasurement gain in the quarter.
The company issued 780,264 shares to its CEO as part of an initial equity grant, recognizing $142,633 in stock‑based compensation in Q3. As a subsequent event, outstanding debt totaling $4,166,946.69 was converted into common stock at $0.25 per share, and the Board approved additional equity issuances at the same price. Shares outstanding were 46,852,319 as of November 13, 2025.